Rajesh Devraj
Consultant / Advisor chez DECIPHERA PHARMACEUTICALS, INC.
Profil
Raj is a venture partner and the president and CEO of Rectify Pharmaceuticals.
Previously he co-founded and was chief scientific officer of Disarm Therapeutics until its sale to Eli Lilly in 2020, and was CSO of Padlock Therapeutics until its sale to BMS in 2016.
Before that Raj was president and chief executive officer of Euclises Pharmaceuticals and senior vice president of Deciphera Pharmaceuticals.
Prior to that, he was senior vice president of Jubilant Drug Discovery & Development.
Raj spent 14 years in positions of increasing responsibility with Pfizer Global R&D and legacy Pharmacia and Searle companies.
He has led multiple discovery & early clinical development teams that have advanced eight candidates into clinical trials for refractory cancers, rheumatoid arthritis, diabetic nephropathy, COPD, and pain.
Postes actifs de Rajesh Devraj
| Sociétés | Poste | Début |
|---|---|---|
| DECIPHERA PHARMACEUTICALS, INC. | Consultant / Advisor | 01/12/2012 |
Euclises Pharmaceuticals, Inc.
 Euclises Pharmaceuticals, Inc. Hospital/Nursing ManagementHealth Services Euclises Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm develops a portfolio of COX-2 inhibitors optimized for cancer treatment based on its proprietary Euclicoxib platform and is in the process of selecting a lead clinical development candidate. The company was founded by John J. Talley in 2011 and is headquartered in St. Louis, MO. | Directeur/Membre du Conseil | 27/01/2015 |
Disarm Therapeutics, Inc.
 Disarm Therapeutics, Inc. BiotechnologyHealth Technology Disarm Therapeutics, Inc. engages in the development of therapeutics to treat patients with neurological diseases. It includes multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies. The company was founded by Jason Rhodes, Jeffrey Milbrandt, Raul Krauss, Aaron DiAntonio, and Rajesh Devraj on October 21, 2016 and is headquartered in Cambridge, MA. | Fondateur | 21/10/2016 |
Atlas Venture Advisors, Inc.
 Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Private Equity Investor | 01/11/2020 |
Rectify Pharmaceuticals LLC
 Rectify Pharmaceuticals LLC Miscellaneous Commercial ServicesCommercial Services Rectify Pharmaceuticals LLC is a biotech company that is developing positive functional modulators (PFMs) to address the underlying cause of serious ABC transporter-mediated diseases. The company is based in Cambridge, MA and was founded by Jonathan Moore. The company's team includes Xiaobing Li as Chief Development Officer, Robert Hughes as Executive Vice President of Drug Discovery and Preclinical Development, and Leif-Ann Tuohey as Senior Vice President and Head of Business Development. The company has received $100 million in Series A financing from Atlas Venture, Omega Funds, Forbion, and Longwood Fund. The CEO is Rajesh Devraj, who is also a venture partner at Atlas Venture. | Directeur Général | 01/04/2021 |
Anciens postes connus de Rajesh Devraj
| Sociétés | Poste | Fin |
|---|---|---|
Indalo Therapeutics, Inc.
 Indalo Therapeutics, Inc. BiotechnologyHealth Technology Indalo Therapeutics, Inc. operates as a biopharmaceutical firm that develops integrin antagonists for patients suffering from serious fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). The company was founded by David Griggs, Williamson Z. Bradford III, Peter Ruminski, and Robert W. Karr and is headquartered in Cambridge, MA. | Directeur/Membre du Conseil | 30/06/2020 |
Antegrin Therapeutics LLC
 Antegrin Therapeutics LLC Pharmaceuticals: MajorHealth Technology Antegrin Therapeutics LLC develops novel therapies for fibrotic diseases. It focuses on idiopathic pulmonary fibrotic diseases, which are conditions that involve out-of-control scarring of organs. The company was founded by David Griggs and Peter Ruminski in 2012 and is headquartered in St. Louis, MO. | Président | 30/08/2016 |
Padlock Therapeutics, Inc.
 Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | Directeur Technique/Scientifique/R&D | 31/03/2016 |
Jubilant Biosys Ltd.
 Jubilant Biosys Ltd. BiotechnologyHealth Technology Jubilant Biosys Ltd. specializes in drug discovery services, proprietary in-house innovation, and strategic investments. Its services include discovery informatics, computational chemistry, structural biology, chemistry, in vitro and in vivo biology, and toxicology. The company was founded by VN Balaji in 2001 and is headquartered in Noida, India. | Private Equity Investor | 31/07/2011 |
| ░░░░░░░ ░░░░ ░░░░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
Formation de Rajesh Devraj
| Duquesne University of The Holy Spirit | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| DECIPHERA PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 10 |
|---|---|
Euclises Pharmaceuticals, Inc.
Euclises Pharmaceuticals, Inc. Hospital/Nursing ManagementHealth Services Euclises Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm develops a portfolio of COX-2 inhibitors optimized for cancer treatment based on its proprietary Euclicoxib platform and is in the process of selecting a lead clinical development candidate. The company was founded by John J. Talley in 2011 and is headquartered in St. Louis, MO. | Health Services |
Tansna Therapeutics, Inc.
 Tansna Therapeutics, Inc. Medical DistributorsDistribution Services Tansna Therapeutics, Inc. develops and offers oral drugs to treat epilepsy. It focuses on novel therapies for the treatment of central nervous system disorders. The company was founded by Max Baker in 2010 and is headquartered in St. Louis, MO. | Distribution Services |
Atlas Venture Advisors, Inc.
Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Jubilant Biosys Ltd.
Jubilant Biosys Ltd. BiotechnologyHealth Technology Jubilant Biosys Ltd. specializes in drug discovery services, proprietary in-house innovation, and strategic investments. Its services include discovery informatics, computational chemistry, structural biology, chemistry, in vitro and in vivo biology, and toxicology. The company was founded by VN Balaji in 2001 and is headquartered in Noida, India. | Health Technology |
Antegrin Therapeutics LLC
Antegrin Therapeutics LLC Pharmaceuticals: MajorHealth Technology Antegrin Therapeutics LLC develops novel therapies for fibrotic diseases. It focuses on idiopathic pulmonary fibrotic diseases, which are conditions that involve out-of-control scarring of organs. The company was founded by David Griggs and Peter Ruminski in 2012 and is headquartered in St. Louis, MO. | Health Technology |
Padlock Therapeutics, Inc.
Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | Health Technology |
Indalo Therapeutics, Inc.
Indalo Therapeutics, Inc. BiotechnologyHealth Technology Indalo Therapeutics, Inc. operates as a biopharmaceutical firm that develops integrin antagonists for patients suffering from serious fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). The company was founded by David Griggs, Williamson Z. Bradford III, Peter Ruminski, and Robert W. Karr and is headquartered in Cambridge, MA. | Health Technology |
Disarm Therapeutics, Inc.
Disarm Therapeutics, Inc. BiotechnologyHealth Technology Disarm Therapeutics, Inc. engages in the development of therapeutics to treat patients with neurological diseases. It includes multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies. The company was founded by Jason Rhodes, Jeffrey Milbrandt, Raul Krauss, Aaron DiAntonio, and Rajesh Devraj on October 21, 2016 and is headquartered in Cambridge, MA. | Health Technology |
| Pfizer, Inc. /India/ | |
Rectify Pharmaceuticals LLC
Rectify Pharmaceuticals LLC Miscellaneous Commercial ServicesCommercial Services Rectify Pharmaceuticals LLC is a biotech company that is developing positive functional modulators (PFMs) to address the underlying cause of serious ABC transporter-mediated diseases. The company is based in Cambridge, MA and was founded by Jonathan Moore. The company's team includes Xiaobing Li as Chief Development Officer, Robert Hughes as Executive Vice President of Drug Discovery and Preclinical Development, and Leif-Ann Tuohey as Senior Vice President and Head of Business Development. The company has received $100 million in Series A financing from Atlas Venture, Omega Funds, Forbion, and Longwood Fund. The CEO is Rajesh Devraj, who is also a venture partner at Atlas Venture. | Commercial Services |
